EXEMESTANE Drug Patent Profile
✉ Email this page to a colleague
When do Exemestane patents expire, and what generic alternatives are available?
Exemestane is a drug marketed by Alvogen, Amneal Pharms, Breckenridge, Cipla, Dr Reddys Labs Sa, Eugia Pharma, Hikma, Qilu, Rising, Upsher Smith Labs, and Zydus Pharms. and is included in eleven NDAs.
The generic ingredient in EXEMESTANE is exemestane. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the exemestane profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Exemestane
A generic version of EXEMESTANE was approved as exemestane by HIKMA on April 1st, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EXEMESTANE?
- What are the global sales for EXEMESTANE?
- What is Average Wholesale Price for EXEMESTANE?
Summary for EXEMESTANE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 11 |
| Raw Ingredient (Bulk) Api Vendors: | 100 |
| Clinical Trials: | 254 |
| Drug Prices: | Drug price information for EXEMESTANE |
| What excipients (inactive ingredients) are in EXEMESTANE? | EXEMESTANE excipients list |
| DailyMed Link: | EXEMESTANE at DailyMed |
Recent Clinical Trials for EXEMESTANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Breast Cancer Research Foundation | Phase 2 |
| QuantumLeap Healthcare Collaborative | Phase 2 |
| NRG Oncology | Phase 2 |
Pharmacology for EXEMESTANE
| Drug Class | Aromatase Inhibitor |
| Mechanism of Action | Aromatase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for EXEMESTANE
US Patents and Regulatory Information for EXEMESTANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen | EXEMESTANE | exemestane | TABLET;ORAL | 200898-001 | Jul 28, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hikma | EXEMESTANE | exemestane | TABLET;ORAL | 077431-001 | Apr 1, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cipla | EXEMESTANE | exemestane | TABLET;ORAL | 210323-001 | Apr 27, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Qilu | EXEMESTANE | exemestane | TABLET;ORAL | 213547-001 | Apr 13, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Amneal Pharms | EXEMESTANE | exemestane | TABLET;ORAL | 206421-001 | Dec 28, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Breckenridge | EXEMESTANE | exemestane | TABLET;ORAL | 211031-001 | Feb 21, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Eugia Pharma | EXEMESTANE | exemestane | TABLET;ORAL | 216454-001 | May 20, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
